Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

Minimal residual disease (MRD) is associated with adverse outcome in AML after myeloablative (MA) hematopoietic cell transplantation (HCT). We compared this association with that seen after nonmyeloablative (NMA) conditioning in 241 adults receiving NMA (n=86) or MA (n=155) HCT for AML in first remi...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, Roland B., Gyurkocza, Boglarka, Storer, Barry E., Godwin, Colin D., Pagel, John M., Buckley, Sarah A., Sorror, Mohamed L., Wood, Brent L., Storb, Rainer, Appelbaum, Frederick R., Sandmaier, Brenda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254901/
https://www.ncbi.nlm.nih.gov/pubmed/24888275
http://dx.doi.org/10.1038/leu.2014.173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254901/
https://www.ncbi.nlm.nih.gov/pubmed/24888275
http://dx.doi.org/10.1038/leu.2014.173

Ejemplares similares